Royal Bank of Canada
BEAM icon

Royal Bank of Canada’s Beam Therapeutics BEAM Stock Holding History

Royal Bank of Canada’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$401K Buy
16,825
+1,144
+7% +$31.7K ﹤0.01% 4301
2025
Q4 		$435K Sell
15,681
-400,574
-96% -$10.2M ﹤0.01% 4269
2025
Q3 		$10.1M Sell
416,255
-141,806
-25% -$2.82M ﹤0.01% 2144
2025
Q2 		$9.49M Buy
558,061
+549,878
+6,720% +$9.58M ﹤0.01% 2069
2025
Q1 		$160K Sell
8,183
-2,035
-20% -$53.3K ﹤0.01% 4867
2024
Q4 		$253K Buy
10,218
+1,536
+18% +$39.2K ﹤0.01% 4616
2024
Q3 		$213K Buy
8,682
+68
+0.8% +$1.76K ﹤0.01% 4767
2024
Q2 		$202K Buy
8,614
+4,543
+112% +$112K ﹤0.01% 4759
2024
Q1 		$135K Buy
4,071
+2,135
+110% +$66.5K ﹤0.01% 5008
2023
Q4 		$53K Sell
1,936
-141
-7% -$3.5K ﹤0.01% 5956
2023
Q3 		$50K Sell
2,077
-21,260
-91% -$570K ﹤0.01% 5781
2023
Q2 		$746K Buy
23,337
+1,408
+6% +$45.7K ﹤0.01% 3623
2023
Q1 		$671K Sell
21,929
-3,262
-13% -$129K ﹤0.01% 3643
2022
Q4 		$985K Buy
25,191
+615
+3% +$27.5K ﹤0.01% 3509
2022
Q3 		$1.17M Sell
24,576
-6,901
-22% -$394K ﹤0.01% 3316
2022
Q2 		$1.22M Buy
31,477
+11,691
+59% +$465K ﹤0.01% 3322
2022
Q1 		$1.13M Buy
19,786
+13,650
+222% +$895K ﹤0.01% 3540
2021
Q4 		$489K Buy
6,136
+4,276
+230% +$366K ﹤0.01% 4472
2021
Q3 		$162K Sell
1,860
-2,848
-60% -$286K ﹤0.01% 5349
2021
Q2 		$605K Buy
4,708
+909
+24% +$72.4K ﹤0.01% 4098
2021
Q1 		$304K Buy
3,799
+2,292
+152% +$218K ﹤0.01% 4601
2020
Q4 		$123K Buy
1,507
+1,482
+5,928% +$72.9K ﹤0.01% 5206
2020
Q3 		$1K Buy
25
+4
+19% +$99 ﹤0.01% 6392
2020
Q2 		$1K Sell
21
-32
-60% -$690 ﹤0.01% 6383
2020
Q1 		$1K Buy
+53
New +$1.15K ﹤0.01% 6399

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Royal Bank of Canada's BEAM Position: Q1 2026 in Review

Royal Bank of Canada increased its Beam Therapeutics (BEAM) stake by 7.3% in Q1 2026, buying an estimated $31.7K and bringing the position to 16,825 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #4301.

Royal Bank of Canada first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $10.1M in Q3 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Royal Bank of Canada held 16,825 shares of Beam Therapeutics worth $401K as of Q1 2026.
  • Royal Bank of Canada bought 1,144 Beam Therapeutics shares in Q1 2026, an estimated $31.7K.
  • Beam Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4301 holding.
  • Royal Bank of Canada first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Royal Bank of Canada's Beam Therapeutics position peaked at $10.1M in Q3 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.